- Home
- MODD vs BCTX Comparison
MODD vs BCTX Comparison
Compare MODD & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MODD | BCTX |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 28.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MODD | BCTX |
|---|---|---|
| Price | $0.47 | $4.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 171.3K | ★ 429.3K |
| Earning Date | 02-13-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $4.01 |
| 52 Week High | $1.29 | $98.20 |
Technical Indicators
Market Signals| Indicator | MODD | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 37.31 |
| Support Level | $0.42 | $4.01 |
| Resistance Level | $0.49 | $4.42 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 48.41 | 5.23 |
Price Performance
Historical ComparisonAbout MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.